DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today
October 15, 2020 08:00 ET | Denali Therapeutics Inc.
Proprietary and differentiated Transport Vehicle (TV) technology shows potential to solve the BBB challenge by delivering biotherapeutics to the brainNew preclinical data support the potential for...
Annovis_Corp_Image.png
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
September 29, 2020 06:45 ET | Annovis Bio Inc.
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal...
prevail.png
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 18, 2020 15:04 ET | Prevail Therapeutics
NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
prevail.png
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
August 11, 2020 06:30 ET | Prevail Therapeutics
Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients Company Modifies Protocol for PROPEL...
DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
May 27, 2020 16:30 ET | Denali Therapeutics Inc.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
February 27, 2020 16:30 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2020 20:41 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of...
DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
January 28, 2020 20:58 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its...
Vaccinex logo
Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease
December 09, 2019 07:55 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
August 21, 2019 08:33 ET | Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...